| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
5 companies
Lynx1 Capital Management LP is a 10% Owner at Cullinan Therapeutics, Inc. with holdings across 5 companies. Recent SEC Form 4 filings include 22 buys and 0 sells.
Estimated insider holdings value: $168.7M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | KRRO Korro Bio, Inc. | 10% Owner | Buy | 520 | $10.60 | $5,512.00 | - | - | - | |
| Dec 23, 2025 | TCRX Tscan Therapeutics, Inc. | 10% Owner | Buy | 161,801 | $0.90 | $145,525.97 | +0.7% | +14.2% | - | |
| Oct 28, 2025 | CGEM Cullinan Therapeutics, Inc. | 10% Owner | Buy | 165,667 | $8.40 | $1,391,685.63 | +1.9% | +41.0% | - | |
| Oct 21, 2025 | NEUP Neuphoria Therapeutics Inc. | 10% Owner | Buy | 639,110 | $5.14 | $3,283,108.07 | +270.6% | -16.9% | - | |
| Oct 17, 2025 | CGEM Cullinan Therapeutics, Inc. | 10% Owner | Buy | 248,749 | $8.46 | $2,103,912.01 | +0.7% | +35.7% | - | |
| Oct 10, 2025 | CGEM Cullinan Therapeutics, Inc. | 10% Owner | Buy | 1,459,641 | $6.73 | $9,826,941.41 | +6.3% | +50.5% | - | |
| Sep 15, 2025 | PASG Passage Bio, Inc. | 10% Owner | Buy | 32,008 | $6.99 | $223,734.68 | +1.8% | +44.6% | - | |
| Jul 24, 2025 | PASG Passage Bio, Inc. | 10% Owner | Buy | 128,848 | $5.70 | $733,825.53 | +8.8% | +43.0% | - | |
| May 20, 2025 | TCRX Tscan Therapeutics, Inc. | 10% Owner | Buy | 2,588,794 | $1.20 | $3,106,552.80 | +21.4% | +47.9% | - | |
| Dec 27, 2024 | PASG Passage Bio, Inc. | 10% Owner | Buy | 373,645 | $0.65 | $241,038.39 | +4.2% | -37.1% | -17.4% |